Alcoholic Hepatitis Clinical Trial
Official title:
The Effect of Gut Sterilisation on Macrophage Activation in Patients With Alcoholic Hepatitis.
Alcoholic hepatitis (AH) is a severe alcohol induced hepatic inflammation that leads to
jaundice and liver failure. Gut derived bacterial translocation to the liver is currently
thought to be one of the main inflammatory drivers of the disease.
This project investigates the effects of gut sterilisation with broad spectrum antibiotics in
patients with AH
Alcoholic hepatitis (AH) is a severe alcohol induced hepatic inflammation that leads to
jaundice and liver failure. The incidence of AH is increasing and the disease is associated
with a high mortality. In spite of numerous clinical trials both treatment and prognosis have
remained essentially unchanged for decades, emphasizing the need to improve our understanding
of the disease mechanisms behind AH.
The current perception of the pathogenesis of alcohol-induced liver injury mainly derives
from animal models, and the resident hepatic macrophages, the Kupffer cells, seem to play an
important role. Activation of these cells may give rise to most of the hallmark clinical
findings of AH: The cytokines released initiate hepatic inflammation and an acute phase
response, recruit neutrophils, and activate stellate cells, contributing to the acute portal
hypertension. Jaundice is due to intrahepatic cholestasis caused by down regulation of the
bilirubin transporters on the basolateral hepatocyte membrane. Hepatic macrophages are
thought to be activated by the bacterial derived endotoxins/lipopolysaccharides (LPS) present
in the portal blood because of an alcohol-induced increase in gut-blood permeability with
translocation of bacteria, as found in patients with alcoholic liver injury. LPS is
recognized by the hepatic macrophages via a membrane complex including the pathogen
recognition receptor molecule Toll-like receptor 4 (TLR-4). LPS Binding Proteins (LBP)
produced by hepatocytes then bind and present LPS to the membrane glycoprotein CD14 that in
turn activates TLR-4. In support of these mechanisms, alcohol-induced liver injury is reduced
in knockout mice missing LBP, CD14, and TLR-4. Likewise, chemical destruction of hepatic
macrophages in rats prevents alcohol-induced liver injury, as does cleansing the gut flora
with antibiotics.
Human hepatic macrophages when activated, express their surface receptor CD163. We and others
have previously shown that sCD163 is released from the liver in alcoholic liver disease, that
its plasma concentration predicts mortality in patients with acute liver failure and is as a
marker of portal hypertension and a predictor of clinical decompensation in patients with
liver cirrhosis. Very recently we have directly demonstrated hepatic macrophage activation in
human AH paralleling the disease severity, and to suggest this to be elicited by LPS.
The line of evidence presented above provides rationale for testing whether intervention
toward bacterial translocation may result in a diminished immune response in human AH.
Consequently, in this study the investigators seek to perform total gut microbiota
eradication by combining 3 different orally administered antibiotics. The investigators have
chosen antibiotics that are not absorbed into the systemic circulation, because the
investigators want to limit the effects to the gastrointestinal tract.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04066179 -
Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients.
|
N/A | |
Completed |
NCT03732586 -
Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis
|
N/A | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT00962442 -
N-Acetylcysteine in Severe Acute Alcoholic Hepatitis
|
Phase 3 | |
Not yet recruiting |
NCT06307522 -
MRG-001 in Patients With Alcoholic Hepatitis
|
Phase 2 | |
Recruiting |
NCT05018481 -
HA35 Moderate Alcoholic Hepatitis (AH) Study
|
Early Phase 1 | |
Completed |
NCT04544020 -
Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
|
||
Recruiting |
NCT04088370 -
Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
|
||
Completed |
NCT04235855 -
EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication?
|
N/A | |
Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
Completed |
NCT00851981 -
Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease
|
Phase 2 | |
Completed |
NCT04084522 -
Effect of Saturated Fat (Desi Ghee) on Gut-Liver Axis in Alcoholic Hepatitis
|
N/A | |
Completed |
NCT05840640 -
Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis
|
Phase 4 | |
Recruiting |
NCT03069300 -
N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis
|
Phase 3 | |
Terminated |
NCT02039219 -
Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)
|
Phase 2 | |
Completed |
NCT02019056 -
Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis
|
Phase 2 | |
Completed |
NCT01245257 -
Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis
|
N/A | |
Completed |
NCT00388323 -
Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human
|
N/A | |
Recruiting |
NCT03845205 -
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
|
N/A | |
Recruiting |
NCT03703674 -
GCSF in Alcoholic Hepatitis
|
Phase 4 |